BACKGROUND: Chronic rhinosinusitis (CRS) is likely a biologically heterogeneous disease process. Current guidelines propose subclassification using polyp status while others propose using mucosal eosinophilia. We hypothesized that appropriate CRS subclassification would increase homogeneity of baseline symptoms, and identify characteristic symptoms of each subtype. METHODS: A total of 57 CRS patients undergoing surgery prospectively completed a preoperative battery of 73 questions relating to symptoms including the 22-item Sino-Nasal Outcome Test (SNOT-22) and 29-item Patient-Reported Outcomes Measurement Information System (PROMIS-29) general quality of life (QOL) measures. Eosinophilic cationic protein (ECP) levels were determined from ethmoid, uncinate, and polyp tissue homogenates using enzyme-linked immunosorbent assay (ELISA) and normalized to total protein. Patients were classified as eosinophilic (eCRS) or non-eosinophilic (neCRS) using a 95th percentile threshold established from control tissue from 82 patients without CRS. Separate pairwise comparisons were performed on patient-reported symptoms using polyp and eosinophilic status. RESULTS: Of the 57 patients, 28 had CRS with nasal polyps (CRSwNP); 27 of 57 patients had eCRS (CRSwNP, n = 21; CRS without nasal polyps [CRSsNP], n = 6). CRSwNP patients had increased need to blow nose, frequency of nasal congestion, more severe difficulty breathing through nose, more severe nasal discharge, but less cough (p < 0.05). eCRS patients had more bothersome loss of taste/smell, ear pain, sneezing, severe difficulty breathing through nose, and severe nasal congestion compared to neCRS patients (p < 0.05). CONCLUSION: Subclassifying CRS with symptoms alone is difficult with neither polyp status nor eosinophilia giving a distinctive clinical symptom profile. However, certain symptoms may help otolaryngologists identify CRS subtypes, which may help guide future treatments. Further validation and evaluation of prognosis following treatment is required to evaluate appropriate means of subclassifying CRS.
BACKGROUND:Chronic rhinosinusitis (CRS) is likely a biologically heterogeneous disease process. Current guidelines propose subclassification using polyp status while others propose using mucosal eosinophilia. We hypothesized that appropriate CRS subclassification would increase homogeneity of baseline symptoms, and identify characteristic symptoms of each subtype. METHODS: A total of 57 CRSpatients undergoing surgery prospectively completed a preoperative battery of 73 questions relating to symptoms including the 22-item Sino-Nasal Outcome Test (SNOT-22) and 29-item Patient-Reported Outcomes Measurement Information System (PROMIS-29) general quality of life (QOL) measures. Eosinophilic cationic protein (ECP) levels were determined from ethmoid, uncinate, and polyp tissue homogenates using enzyme-linked immunosorbent assay (ELISA) and normalized to total protein. Patients were classified as eosinophilic (eCRS) or non-eosinophilic (neCRS) using a 95th percentile threshold established from control tissue from 82 patients without CRS. Separate pairwise comparisons were performed on patient-reported symptoms using polyp and eosinophilic status. RESULTS: Of the 57 patients, 28 had CRS with nasal polyps (CRSwNP); 27 of 57 patients had eCRS (CRSwNP, n = 21; CRS without nasal polyps [CRSsNP], n = 6). CRSwNP patients had increased need to blow nose, frequency of nasal congestion, more severe difficulty breathing through nose, more severe nasal discharge, but less cough (p < 0.05). eCRS patients had more bothersome loss of taste/smell, ear pain, sneezing, severe difficulty breathing through nose, and severe nasal congestion compared to neCRS patients (p < 0.05). CONCLUSION: Subclassifying CRS with symptoms alone is difficult with neither polyp status nor eosinophilia giving a distinctive clinical symptom profile. However, certain symptoms may help otolaryngologists identify CRS subtypes, which may help guide future treatments. Further validation and evaluation of prognosis following treatment is required to evaluate appropriate means of subclassifying CRS.
Authors: Sarah Peterson; Julie A Poposki; Deepti R Nagarkar; Regina T Chustz; Anju T Peters; Lydia A Suh; Roderick Carter; James Norton; Kathleen E Harris; Leslie C Grammer; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Robert P Schleimer; Atsushi Kato Journal: J Allergy Clin Immunol Date: 2011-09-23 Impact factor: 10.793
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Moritz Gröger; Andreas Bernt; Maria Wolf; Brigitte Mack; Elisabeth Pfrogner; Sven Becker; Matthias F Kramer Journal: Eur Arch Otorhinolaryngol Date: 2013-02-22 Impact factor: 2.503
Authors: Kornkiat Snidvongs; Matthew Lam; Raymond Sacks; Peter Earls; Larry Kalish; P Seamus Phillips; Eleanor Pratt; Richard J Harvey Journal: Int Forum Allergy Rhinol Date: 2012-03-14 Impact factor: 3.858
Authors: Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald Journal: Rhinol Suppl Date: 2012-03
Authors: Sergei I Ochkur; John Dongil Kim; Cheryl A Protheroe; Dana Colbert; Rachel M Condjella; Sophie Bersoux; Richard A Helmers; Redwan Moqbel; Paige Lacy; Elizabeth A Kelly; Nizar N Jarjour; Robert Kern; Anju Peters; Robert P Schleimer; Glenn T Furuta; Parameswaran Nair; James J Lee; Nancy A Lee Journal: J Immunol Methods Date: 2012-06-28 Impact factor: 2.303
Authors: Bruce K Tan; Aiko I Klingler; Julie A Poposki; Whitney W Stevens; Anju T Peters; Lydia A Suh; James Norton; Roderick G Carter; Kathryn E Hulse; Kathleen E Harris; Leslie C Grammer; Robert P Schleimer; Kevin C Welch; Stephanie S Smith; David B Conley; Robert C Kern; Atsushi Kato Journal: J Allergy Clin Immunol Date: 2016-09-14 Impact factor: 10.793
Authors: Jin-Young Min; Jayakar V Nayak; Kathryn E Hulse; Whitney W Stevens; Paul A Raju; Julia H Huang; Lydia A Suh; Griet A Van Roey; James E Norton; Roderick G Carter; Caroline P E Price; Ava R Weibman; Ali R Rashan; Eliver E Ghosn; Zara M Patel; Tetsuya Homma; David B Conley; Kevin C Welch; Stephanie Shintani-Smith; Anju T Peters; Leslie C Grammer; Kathleen E Harris; Atsushi Kato; Peter H Hwang; Robert C Kern; Leonore A Herzenberg; Robert P Schleimer; Bruce K Tan Journal: J Allergy Clin Immunol Date: 2017-06-16 Impact factor: 10.793
Authors: Whitney W Stevens; Anju T Peters; Bruce K Tan; Aiko I Klingler; Julie A Poposki; Kathryn E Hulse; Leslie C Grammer; Kevin C Welch; Stephanie S Smith; David B Conley; Robert C Kern; Robert P Schleimer; Atsushi Kato Journal: J Allergy Clin Immunol Pract Date: 2019-05-22
Authors: Alcina K Lidder; Kara Y Detwiller; Caroline P E Price; Robert C Kern; David B Conley; Stephanie Shintani-Smith; Kevin C Welch; Rakesh K Chandra; Anju T Peters; Leslie C Grammer; Li-Xing Man; Robert P Schleimer; Bruce K Tan Journal: Int Forum Allergy Rhinol Date: 2016-11-07 Impact factor: 3.858
Authors: Ava R Weibman; Julia He Huang; Whitney W Stevens; Lydia A Suh; Caroline P E Price; Alcina K Lidder; David B Conley; Kevin C Welch; Stephanie Shintani-Smith; Anju T Peters; Leslie C Grammer; Atsushi Kato; Robert C Kern; Robert P Schleimer; Bruce K Tan Journal: Int Forum Allergy Rhinol Date: 2017-09-01 Impact factor: 3.858